

## Correction to *Lancet Oncol* 2016; 17: 1590–98

Sharma P, Callahan MK, Bono P, et al. *Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.* *Lancet Oncol* 2016; **17**: 1590–98—In this Article, the declaration of interests should read “PSh has received fees for advisory board participation for Jounce and Kite; fees for consultancy from Jounce, Kite, Bristol-Myers Squibb, AstraZeneca, and Amgen; and stock or stock options from Jounce and Kite. MKC has received grants from Bristol-Myers Squibb; consultancy fees from AstraZeneca and Moderna; and payment for lectures from Clinical Care Options. PB has received honoraria from Bristol-Myers Squibb, Pfizer, MSD, and Orion Pharma, and research funding from Novartis. JK has received research funding from Immune Design; and consultancy fees from Valeant Pharmaceutical, Voluntas, and Genentech/Roche. ECa reports research grants and/or financial support from Boehringer Ingelheim, Roche/Genentech, Bristol-Myers Squibb, Novartis, PsiOxus, Nanobiotix Janssen, AbbVie, PharmaMar, PUMA, Sanofi, Lilly, Pfizer, Merck, Nektar, Amcure, Amgen, AstraZeneca, Principia, Bayer, CytomX, H3, Incyte, Kura, LOXO, MacroGenics, Menarini, Merck Serono, Merus, Millenium, Rigontec, Tahio, and BeuGene Tesaro; consultancy fees from Janssen-Cilag, Alkermes (and travel expenses), Seattle Genetics, Pierre Fabre, Cerulean Pharma, EUSA, Celgene, Novartis (speakers’ bureau), Nanobiotix, PsiOxus Therapeutics, AbbVie, AstraZeneca, Guidepoint Global, Roche/Genentech (and travel expenses), GLG, Pfizer, Servier, Amcure, and Boehringer Ingelheim; ownership from START (leadership), Oncoarts Associated and International Cancer Consultants; and employment from START and HM Hospitals

Group (honoraria) and president and founder of NPO Foundation Intheos (Investigational Therapeutics in Oncological Sciences), outside the submitted work. RNP has received a travel grant from Bristol-Myers Squibb for an investigator meeting. PAO has received a grant from Bristol-Myers Squibb and consultancy fees from Bristol-Myers Squibb, Amgen, Celldex, Alexion, and Cytomx. FdB has received consultancy fees from Tiziana Life Sciences, Bristol-Myers Squibb, MSD, Servier, Eli Lilly, Merck Serono, GlaxoSmithKline, and Novartis, and speaker fees from Bristol-Myers Squibb, Eli Lilly, Roche, and ACCMED. MM has received consultancy fees from Etubics and Boehringer Ingelheim, and speaker fees from Genentech, Novartis, Sanofi, Regeneron, Lexicon, Ipsen, Onyx, Bayer, Taiho, Merrimack, and Celgene. AA is an employee of Bristol-Myers Squibb. DJ has received consulting fees from Definiens, F Hoffmann-La Roche, CureVac, Roche Pharma, Novartis Pharma, and Novartis Oncology-Novartis Farma, outside the submitted work; and has a patent issued for intellectual property of infiltrating T-cell density predicting outcome. ECh has received grants from Bristol-Myers Squibb and consultancy fees for advisory board participation from EMD Serono, Taiho, Bayer, Advaxis, Amgen, Lilly, and Castle Biosciences. CH, C-SL, and MT are employees of and hold stock options with Bristol-Myers Squibb. JER has received grants for study conduct from Novartis; funds for clinical trial conduct from Astellas, Seattle Genetics, Bayer, AstraZeneca, Mirati Therapeutics, Oncogenex, and Roche/Genentech; has received consultancy fees from Roche/Genentech, AstraZeneca, Eli Lilly, Astellas, Seattle Genetics, Bristol-Myers Squibb, Merck, EMD-Serono, Adicet Bio, western oncolytics, Pharmacyclics, Sensei Biotherapeutics, Bayer, BioClin Therapeutics, QED Therapeutics, Mirati Therapeutics, Fortress Biotech, Gritstone Oncology, Inovio; has received honoraria from Bristol-Myers

Squibb and Chugai; has held stock in Illumina and Merck. PSp and DTL declare no competing interests.” This correction has been made to the online version as of Feb 1, 2019.

## Correction to *Lancet Oncol* 2017; 18: 904–16

Baselga J, Im S-A, Iwata H, et al. *Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.* *Lancet Oncol* 2017; **18**: 904–16—In this Article, the declaration of interests should read “JB has received reimbursement for travel, and advisory board and consulting fees from Novartis, during the conduct of the study; has received personal fees and held stock as a member of the board of directors from Aura Biosciences; has received personal fees as a member of the advisory board and held stock as a founder of Northern Biologics (f/k/a Mosaic Biomedicals); has received personal fees and held stock as a member of the board of directors from Infinity Pharmaceuticals; held stock as a member of the advisory board from ApoGen Biotechnologies; has received personal fees and held stock as a member of the advisory board from PMV Pharma; has received personal fees and held stock as a member of the advisory board from Juno Therapeutics; has received personal fees and held stock as co-founder from TANGO (f/k/a Synthetic Lethal); has received personal fees and held stock as a member of the scientific advisory board and the board of directors from GRAIL; has received personal fees and held stock as a member of board of directors from Varian Medical Systems; held stock as a member of board of directors from Foghorn Therapeutics; has received reimbursement for travel,